News

NSF Awards NOVA’s Biotechnology Program $550,000 for NOBLE Project

The NOVA Biotechnology and Leadership in Education (NOBLE) Project will be funded by the National Science Foundation with more than $550,000 over the next three years. The goal of the NOBLE Project is to revitalize and grow the biotechnology program. The NOBLE Project seeks to recruit students throughout the entire NOVA service area, particularly minorities in STEM, veterans and dual-enrollment students. The NOBLE Project will include faculty from the Alexandria and Manassas campuses.

The goal of the NOBLE Project is to train students in technical and professional skills to increase their competitiveness in the biotechnology job market. Students will gain additional key experiences by attending scientific conferences and connecting with scientific organizations. Importantly, the grant will provide funds for paid internships at local biotechnology companies. Work will begin this summer. Interested students should contact Xin Zhou at xzhou@nvcc.edu or David Fernandez at dfernandez@nvcc.edu.

The principle investigator (PI) of this project, Dr. David Fernandez, thanks Dr. Eun-Woo Chang, vice president of academic affairs and chief academic office; Dr. Xin Zhou, NOVA biotechnology program head; Dr. Maggie Emblom-Callahan, interim dean of MSTB Alexandria and Dr. Diane Mucci, Annandale Campus provost, for their guidance and vision in crafting this project.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep